# IAP3 Rec'd PCT/PTO 20 MAR 2006

Form PTO (REV 5-93)	1390 U.S. DEPARTMENT OF COM	IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER PB60516			
T	RANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/572671			
	ATIONAL APPLICATION NO. EP2004/010845	INTERNATIONAL FILING DATE 23 September 2004	PRIORITY DATE CLAIMED 25 September 2003			
PIPER	FINVENTION RAZINYL-QUINOLINE RDERS	E DERIVATIVES USEFUL F	OR THE TREATMENT OF CNS			
	ANT(S) FOR DO/EO/US opher Norbert JOHNSC	ON, Stephen Frederick MOSS,	, David R. WITTY			
	nt herewith submits to the Ui formation:	nited States Designated/Elected Offi	ice (DO/EO/US) the following items and			
2. []	This is a <b>SECOND</b> or <b>SUB</b> This express request to begin	_	ncerning a filing under 35 U.S.C. 371. (35 U.S.C. 371(f)) at any time rather than			
	The US has been elected (A					
5. [X]	<ul><li>a. [] is transmitted herew</li><li>b. [x] has been transmitted</li></ul>	Application as filed (35 U.S.C. 371 with (required only if not transmitted d by the International Bureau. the application was filed in the Unite				
6. []	A translation of the Internat	tional Application into English (35 U	J.S.C. 371(c)(2)).			
<ul> <li>7. [x] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</li> <li>a. [] are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [] have been transmitted by the International Bureau.</li> <li>c. [] have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. [x] have not been made and will not be made.</li> </ul>						
8. []		nents to the claims under PCT Artic				
9. [x]		te inventor(s) (35 U.S.C. 371(c)(4)). part of the international application u				
10. []	A translation of the annexes U.S.C. 371(c)(5)).	s to the International Preliminary Ex	amination Report under PCT Article 36 (35			
		er document(s) or information inc				
		Statement under 37 C.F.R. 1.97 and				
12. []	An assignment document to and 3.31 is included.	or recording. A separate cover sheet	in compliance with 37 C.F.R. 3.28			
13. [x]	A FIRST preliminary amen					
14 []		Preliminary Amendment for US	originating cases only)			
	A SECOND of SUBSEQUIA substitute specification.	ENT preliminary amendment.				
		espondence Address Indication For	n.			
	An Abstract on a separate s					
	Copy of Form PCT/ISA/210					
19. [x]	Other items or information:	Statement under 37 CRF 3.73(b) ar	nd copy of			

	NO. (if known see 37 CFR	ATTORNEYS DOCKET NO. PB60516			
	lowing fees are subm	CALCULATION	PTO USE ONLY		
	National Fee (37 C.I				
➤ Basic I	Filing Fee		\$300.00	\$300.00	_
Examin	nation Fee				!
		tion Report prepared by			
	•		\$0.00	\$200.00	
			\$200.00		
■ Search					
			tional application to the		ł
			\$100.00	\$400.00	
		ice\$400.00			
*All other situ	ations	5000 00			
0 1 6012			E CALCULATIONS =	\$900.00	<u> </u>
	0.00 for furnishing the earliest claimed priori	\$0.00			
Claims	Number Filed				
		Number Extra	Rate	00.00	
Total claims	4 - 20 =	0	0 x \$50.00	\$0.00	
Independent claims	1 - 3 =	0	0 x \$200.00	\$0.00	
Multiple depende	nt claims (if applicab	\$0.00			
		TOTAL OF ABO	VE CALCULATIONS =	\$900.00	
	pplication size fee-for	\$0.00			
	heets. The fee is \$25	0.00 for each addtion	al 50 sheets or fraction		
thereof.			SUBTOTAL =		
		\$900.00			
		g the English translati			
☐ 20 ☐ 30 mon	ths from the earliest c	laimed priority date (3	7 CFR 1.492(f)) + FAL NATIONAL FEE =		
		\$900.00			
				Amount to be	\$
				refunded	
		charged	\$		

а. Г	Π.	A check in	the amount of	\$ to	cover th	ne above	fees is	enclosed.
------	----	------------	---------------	-------	----------	----------	---------	-----------

- b. Please charge my Deposit Account No. 19-2570 in the amount of \$900.00 to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5019
Facsimile (610) 270-5090

SIGNATURE

Soma G. Simop

NAME 37,444

REGISTRATION NO.

## 10/572671 MASSICAPETIFIO 20 MAR 2006

#### **PATENT** ATTORNEY'S DOCKET NUMBER PB60516

### TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/EP2004/010845

23 September 2004

25 September 2003

TITLE OF INVENTION

PIPERAZINYL-QUINOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS **DISORDERS** 

APPLICANT(S) FOR DO/US

Christopher Norbert JOHNSON, Stephen Frederick MOSS, David R. WITTY

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450 ATTENTION: DO/US

#### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date March 20, 2006 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV757864997US addressed to the:

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

20462

CUSTOMER NUMBER